Pharma Manufacturing · Jun 2026
External coverage of the LV launch, emphasizing the platform expansion into LV manufacturing and the CHO/biologics direction.
Enabling next generation medicines. A comprehensive platform and…
Company research
Public company, workplace, funding, and market signals
Overview
64x Bio is a Brisbane, California-based biotechnology company spun out of Harvard/Wyss that builds the VectorSelect platform and Apex Suite product lines to engineer higher-yield production cell lines and manufacturing systems for advanced therapies, especially AAV and lentiviral vectors, with biologics expansion underway.
Primary product
VectorSelect platform (including AAV Apex Suite and LV Apex Suite)
Founded
2018
Headquarters
1000 Marina Blvd, Suite 100, Brisbane, CA 94005
Team size
10-20
Industry
Biotechnology Research
Sub-industry
Synthetic biology / gene therapy manufacturing
Offices
Brisbane, CA
Boston, MA
San Francisco, CA
Business model
B2B platform licensing
productized cell-line and production-suite offerings
custom partnership R&D
biopharma/CDMO collaborations
Funding
Stage
Series A
Total raised
$60.5M
Latest round
Series A · Jan 2022
Latest amount
$55M
People & investors
Leadership
Co-founder & CEO
Co-founder, Scientific Advisory Board
Co-founder, Scientific Advisory Board
Co-founder, Advisor
Co-founder, Advisor
Chief Financial Officer
Board of Directors, Advisor
Work & culture
Public sources portray a mission-driven, interdisciplinary team of scientists, engineers, and entrepreneurs focused on scaling advanced medicine manufacturing. The company emphasizes collaboration, rapid product iteration, and hiring across scientific, commercial, and operations functions, but public benefit details are sparse.
Compensation
Public compensation signals are limited. Third-party estimates suggest average annual pay around $115,764, with a typical range of about $101,981 to $130,731, but these figures are not company-confirmed.
Product & market
Pricing
Public pricing is not disclosed; the company appears to sell via B2B partnerships, licensing, and custom collaboration deals.
Differentiators
- —CellMap-driven VectorSelect platform
- —proprietary genetic barcoding linking genotype to productivity
- —massively parallel screening of millions of candidates
- —product suites spanning AAV, lentivirus, and future biologics
- —off-the-shelf products plus custom engineering collaborations
Technology
Knockout.js
Python
JavaScript
D3.js
computational biology
genetic engineering
cell line engineering
next-generation sequencing
proprietary genetic barcoding
massively parallel pooled screening
machine learning
CellMap dataset
VectorSelect platform
Customers
Pharmaceutical companies
Biotechnology companies
CDMOs
gene therapy developers
CAR-T developers
Competitors
Kytopen
Arcellx
Castle Creek Biosciences
Scale & contact
Estimated revenue
$1M-$10M
Estimated monthly visits
3.1K
Latest news
64x Bio · Jun 2026
Official announcement of LV Apex Suite, extending VectorSelect from AAV into lentiviral vector production and signaling further biologics expansion.
Business Wire · Jun 2025
Official AAV product launch, with reported collaborations from major biopharma/CDMO partners and titers exceeding E15 vg/L.
Business Wire · Jan 2022
Series A financing announcement led by Lifeforce Capital to scale VectorSelect and grow the team and partnerships.
64x Bio · Nov 2020
Stealth-emergence post describing the underlying screening/barcoding technology and early seed funding.
Jobs and careers at 64x Bio
0 jobs at 64x Bio
No open positions
Check back later for new openings